MagForce AG

  • WKN: A0HGQF
  • ISIN: DE000A0HGQF5
  • Land: Deutschland

Nachricht vom 30.09.2021 | 08:00

MagForce AG and CHIP Hospital Málaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain agForce AG:

DGAP-News: MagForce AG / Key word(s): Expansion
30.09.2021 / 08:00
The issuer is solely responsible for the content of this announcement.

MagForce AG and CHIP Hospital Málaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain

- Complejo Hospitalario Integral Privado (CHIP) will be first clinic in Spain to offer MagForce's technology for the commercial treatment of brain cancer patients

- Additionally, an investigator-initiated trial (IIT) is planned to be conducted at the public Carlos Haya University Hospital Málaga to support patient reimbursement in Andalusia

- Agreement represents important milestone in MagForce's European roll-out strategy of the NanoTherm therapy system for the treatment of brain tumors

Berlin, Germany, September 30, 2021 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today that it has entered into a collaboration agreement with Complejo Hospitalario Integral Privado (CHIP), Málaga, Spain, for the commercial treatment of brain cancer patients with the NanoTherm therapy system in Andalusia.

The NanoTherm treatment center at CHIP will be headed by the General Director Toni Serra together with the treating neurosurgeon Prof. Miguel Angel Arraez. The private clinic in Málaga will be equipped with MagForce's 'plug-and-treat' solution - a mobile container fully operational with a pre-installed NanoActivator device. This will allow for a significantly shortened time to start patient treatments at the new center. Subject to inspections and permissions by local authorities, commercial treatments are expected to commence in Q1/2022.

The General Director of the CHIP Clinic, Toni Serra said: "We are proud to actively participate in the NanoTherm project, contributing the capacity of our center in the management of all types of pathologies, including complex oncology of all organs, among which is neoplastic pathology of the nervous system. CHIP Hospital performs more than 7,800 operations a year at its facilities, most part of them as partners of Carlos Haya Regional Hospital, in Málaga. We have a medical team of 147 doctors from more than 30 specialties, including Neurosurgery. Our mission is to provide innovative, effective medical treatments to those in dire need of them and we therefore strive for constant improvement while emphasising the quality of our service. We are proud to offer NanoTherm therapy in Málaga, as the first hospital in Spain to do so, and thereby give our patients access to this state-of-the-art treatment option."

Due to the aggressive nature of glioblastoma, timely availability is a decisive factor in the treatment of brain tumors as there is only a narrow window for patients to receive treatment. The collaboration agreement between CHIP Málaga is MagForce's second collaboration outside of Germany and an important achievement in the European roll-out plan of the Company. Magforce intends to enable patients to be treated with the NanoTherm therapy system in their home country and thereby provide faster access to the treatment after this devastating diagnosis.

In addition to the collaboration for commercial treatments, an investigator-initiated trial (IIT) is planned with the NanoTherm therapy system at Carlos Haya University Hospital Málaga. The outcome of the trial will be used to apply for general reimbursement. The trial is planned to be led by Prof. Miguel Arraez, Head of the Neurosurgery Department at the Carlos Haya University Hospital and Professor of Neurosurgery at the University of Málaga, and Dr. Jorge Contreras, Professor with the Faculty of Medicine at the University of Málaga and attending physician with the Radiation Oncology Service of the Carlos Haya Hospital Complex in Málaga as well as Oncology Coordinator at GenesisCare Málaga. As President of the Spanish Radiation Oncology Society (SEOR), Dr. Contreras is a strong advocate for the implementation of hyperthermia in cancer treatment in Spain. It is planned that patients, who are enrolled in the IIT, will have the nanoparticles inserted at the university clinic and will then be transferred to CHIP to be treated in the NanoActivator.

"Over the course of my 30 plus years in medicine, the treatment of cancer has changed dramatically with the emergence of new drugs and technical modalities. When I started my career, hyperthermia was still in its infancy but already showed great promise in the lab. Today, thermotherapy is being successfully applied to treat cancer patients, and I strongly believe that it has the potential to become another important pillar in cancer treatment, together with surgery, radio- and chemotherapy. For this reason, I am thrilled to work with MagForce to introduce this novel approach for patients in Spain," said Dr. Jorge Contreras, provided for Co-Principal Investigator of the IIT. "Since decades of no real progress in Glioblastoma treatment, in particular in the recurrent situation, I can't wait until this nanomedicine based new treatment option will be available very soon in Spain as it is used successfully in Germany and Poland since several years already", said the neurosurgeon Prof. Miguel Angel Arraez, being First Vice President of the World Federation of Neurosurgical Societies (WFNS) and Vice-President of the World Academy of Neurological Surgery.

"Dr. Contreras is pioneer and advocate for the treatment of cancer with thermal therapy and is internationally renowned for his work in this field. We are delighted to be able to support him in his quest to establish this treatment modality in Spain. The NanoTherm treatment center's strategic location at Complejo Hospitalario Integral Privado in Málaga will allow a large number of patients from the autonomous region Andalusia and other regions of Spain, as well as other countries abroad to get access to the therapy. I very much look forward to working with this medical expert and his highly experienced team," said Dr. Andreas Jordan, Executive Vice President and Managing Director Europe of MagForce AG.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.


For more information, please visit: www.magforce.com
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list

Disclaimer

This release may contain forward-looking statements and information which may be identified by terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

 

Contact:
Barbara von Frankenberg
VP Communications & Investor Relations
P +49-30-308380-77
M bfrankenberg@magforce.com

 



30.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021